<DOC>
	<DOC>NCT01117792</DOC>
	<brief_summary>The primary objective is to evaluate the S-ICD system's ability to identify and terminate induced ventricular fibrillation in patients during the implant procedure. The safety and performance of the S-ICD system will also be assessed throughout the patient follow-up period.</brief_summary>
	<brief_title>Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation</brief_title>
	<detailed_description />
	<criteria>Replacement of an existing implanted transvenous ICD system Class I, Class IIa, or Class IIb ACC/AHA/HRS indications for patients without an existing transvenous ICD system Age is &gt;= 18 years Appropriate preoperative ECG as measured with a specially developed template Subjects unable or unwilling to provide informed consent Any condition which precludes the subject's ability to comply with the study requirements Females who are pregnant or lactating and premenopausal women who are unwilling to use adequate birth control for the duration of the study Participation in another investigational device trial at any time during the conduct of the SICD system trial without written consent from the sponsor. Patients with a serious medical condition and life expectancy of less than one year. Patients with documented spontaneous and frequently recurring VT that is reliably terminated with antitachycardia pacing Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant Patients with impaired kidney function as measured by a CockcroftGault Glomerular Filtration Rate (GFR) with a GFR &lt;= 29.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>